Who Owns Lamisil?

What does Haleon own?
Haleon owns a portfolio of approximately 24 global and regional consumer health brands across five categories: oral health, vitamins and supplements, pain relief, respiratory health, and digestive health. Key brands include Sensodyne, Panadol, Centrum, Advil, Voltaren, Otrivin, Parodontax, Polident and Poligrip, Aquafresh, and Emergen-C. Products are sold in more than 170 countries.

Is Haleon publicly traded?
Yes. Haleon plc is listed on the London Stock Exchange under ticker HLN, with American Depositary Shares also listed on the New York Stock Exchange under the same ticker. Haleon completed its listing on the London Stock Exchange on July 18, 2022, in what was the largest London Stock Exchange listing in over a decade. The company does not have a controlling shareholder.

Who founded Haleon?
Haleon was formed through the demerger of GSK's consumer healthcare division in July 2022 and does not have a traditional founder. The consumer healthcare business that became Haleon was assembled by GSK and Pfizer through decades of acquisitions. In 2019, GSK and Pfizer combined their consumer healthcare businesses into a joint venture, which was subsequently demerged as Haleon in 2022. Brian McNamara became CEO at the time of the demerger.

Where is Haleon headquartered?
Haleon is headquartered in Weybridge, Surrey, United Kingdom. The company's registered office and principal executive offices are located in Weybridge. Haleon operates manufacturing facilities in the United Kingdom, the United States, India, Germany, Ireland, and China. The company sells products in more than 170 countries.

How many brands does Haleon own?
Haleon owns approximately 24 global and regional consumer health brands. The portfolio is concentrated in five categories: oral health (Sensodyne, Parodontax, Polident, Poligrip, Aquafresh), vitamins and supplements (Centrum, Caltrate, Emergen-C), pain relief (Advil, Panadol, Voltaren), respiratory health (Otrivin, Theraflu, Robitussin), and digestive health (Nexium Control, Tums).

Who owns Haleon?
Haleon plc is a publicly traded company with no controlling shareholder. At the time of the July 2022 demerger, GSK plc and Pfizer Inc. each retained significant stakes in Haleon. Both companies have been reducing their positions through secondary share placements. As of early 2026, both GSK and Pfizer have substantially reduced their stakes, each holding less than 10% of shares. The remaining shares are held by institutional investors and public shareholders.

What is Haleon's revenue?
Haleon reported FY2025 net revenue of approximately GBP 10.2 billion, with organic revenue growth of approximately 4%. The oral health category is the largest and fastest-growing segment, driven by Sensodyne. The company employs approximately 24,000 people and sells products in more than 170 countries.